TY - JOUR
T1 - Variant-specific neutralising antibodies levels induced by the PHH-1 V SARS-CoV-2 vaccine (Bimervax®) by HIPRA
AU - England, Anna
AU - Sung, Julia
AU - Deulofeu, Meritxell
AU - Soler, Laura Ferrer
AU - Hallis, Bassam
AU - Thomas, Kelly
AU - Charlton, Sue
N1 - Publisher Copyright:
© 2024
PY - 2024/12/2
Y1 - 2024/12/2
N2 - SARS-CoV-2 virus variants continue to emerge at an alarming rate due to spontaneous genetic mutations, particularly in the spike protein receptor-binding domain (RBD) portion, which render the virus more likely to escape immunity. So far, the immunity obtained through global primary and/or booster immunisation campaigns has been sufficient to protect the population from new emerging variants of the Omicron lineage. The current approach to update vaccines' antigen composition to new variants to boost immunity may not be sustainable in the long term. It might also be potentially redundant if the mutations are giving rise to variants which induce milder infections and existing vaccines, such as Bimervax®, are still sufficiently protective, as Covid is slowly becoming a seasonal illness. Through measuring neutralising antibody titres in sera from subjects boosted with Bimervax®, we have demonstrated the ability of Bimervax® to induce immune responses against a variety of SARS-CoV-2 variants, ranging from earlier variants inducing more serious infections to more recent variants which have been found to produce milder infections.
AB - SARS-CoV-2 virus variants continue to emerge at an alarming rate due to spontaneous genetic mutations, particularly in the spike protein receptor-binding domain (RBD) portion, which render the virus more likely to escape immunity. So far, the immunity obtained through global primary and/or booster immunisation campaigns has been sufficient to protect the population from new emerging variants of the Omicron lineage. The current approach to update vaccines' antigen composition to new variants to boost immunity may not be sustainable in the long term. It might also be potentially redundant if the mutations are giving rise to variants which induce milder infections and existing vaccines, such as Bimervax®, are still sufficiently protective, as Covid is slowly becoming a seasonal illness. Through measuring neutralising antibody titres in sera from subjects boosted with Bimervax®, we have demonstrated the ability of Bimervax® to induce immune responses against a variety of SARS-CoV-2 variants, ranging from earlier variants inducing more serious infections to more recent variants which have been found to produce milder infections.
KW - Bimervax®
KW - Neutralising antibodies
KW - SARS-CoV-2 variants
UR - http://www.scopus.com/inward/record.url?scp=85204679582&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/f9977bcf-4d61-3417-ba63-0ed503dda51a/
U2 - 10.1016/j.vaccine.2024.126386
DO - 10.1016/j.vaccine.2024.126386
M3 - Article
AN - SCOPUS:85204679582
SN - 0264-410X
VL - 42
JO - Vaccine
JF - Vaccine
IS - 26
M1 - 126386
ER -